Zobrazeno 1 - 10 of 212 pro vyhledávání: '"Machnig T"'
1
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor
Autor: Longhurst, H, Cicardi, M, Craig, T, Bork, K, Grattan, C, Baker, J, Li, HH, Reshef, A, Bonner, J, Bernstein, JA, Anderson, J, Lumry, WR, Farkas, H, Katelaris, CH, Sussman, GL, Jacobs, J, Riedl, M, Manning, ME, Hebert, J, Keith, PK, Kivity, S, Neri, S, Levy, DS, Baeza, ML, Nathan, R, Schwartz, LB, Caballero, T, Yang, W, Crisan, I, Hernandez, MD, Hussain, I, Tarzi, M, Ritchie, B, Kralickova, P, Guilarte, M, Rehman, SM, Banerji, A, Gower, RG, Bensen-Kennedy, D, Edelman, J, Feuersenger, H, Lawo, JP, Machnig, T, Pawaskar, D, Pragst, I, Zuraw, BL, COMPACT Investigators
Publikováno v: NEW ENGLAND JOURNAL OF MEDICINE
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Scientia
Prevenció; Atac d'angioedema; Inhibidor C1 Prevención; Ataque de angioedema; Inhibidor C1 Prevention; Angioedema attack; C1 inhibitor BACKGROUND: Hereditary angioedema is a disabling, potentially fatal condition caused by deficiency (type I) or dys
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef37114d60fc174570de4929b77385e0
https://doi.org/10.1056/nejmoa1613627
Zobrazit plný text záznamu
2
Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks
Autor: Zuraw, B, Katelaris, C, Sussman, G, Keith, PK, Yang, W, Hebert, J, Hanzlikova, J, Staubach-Renz, P, Martinez-Saguer, I, Magerl, M, Aygoren-Pursun, E, Farkas, H, Reshef, A, Kivity, S, Neri, S, Crisan, I, Caballero, T, Baeza, ML, Hernandez, MD, Li, H, Lumry, W, Bernstein, JA, Hussain, I, Anderson, J, Schwartz, LB, Jacobs, J, Manning, M, Levy, D, Riedl, M, Christiansen, S, Zuraw, BL, Cicardi, M, Craig, T, Longhurst, H, Grattan, C, Bork, K, Kreuz, W, Jacobs, I, Pragst, I, Herget, S, Dalton, S, Clement, C, Mycroft, S, Pawaskar, D, Zhang, Y, Machnig, T, Waldhauser, H, Feuersenger, H, Lawo, JP, Lang, D, Hoernlein, S, Mildenberger, M, Foeller, K, Ellis, F, Wood, D, Walsh, M, Qu, QL, Mueller-Stark, K, Feussner, A, Kalina, U, Ma, X, Rigsby, S, Scheffler, E, Fischer, JF, Kolb, C, Katelaris, CH, Frankum, B, Keat, K, Philip, B, Lee, JA, Urriola, N, Lee, MW, Sussman, GL, Levi, G, Gould, W, Ferrie, P, Rosenberg, E, Waserman, S, O'Quinn, J, Gagnon, R, Vachova, M, Stauerbach-Renz, P, Weber, A, Zimmer, S, Gilfert, T, Lang, B, Escuriola-Ettingshausen, C, Maurer, M, Metz, M, Schoepke, N, Altrichter, S, Hawro, T, Schwabe, D, Graff, J, Behrens, F, Kohm, M, Andarawewa, S, Temesszentandrasi, G, Kohalmi, VK, Kidon, M, Kadar, L, Benor, S, Bonanni, E, Wu, M, Zanichelli, A, Mansi, M, Rizzotto, A, Giardino, F, Fidone, F, Varga, M, Iftene, M, Badiu-Tisa, ID, Cabanas, R, Pedrosa, M, Rivero-Paparoni, D, Gomez-Traseira, C, Alvez, A, Phillips, E, Prieto, A, Zubeldia, J, Ibanez, E, Almero, R, Buckland, M, Grigoriadou, S, Manson, A, Yeatman, N, Laffan, J, Nasr, I, Ghurye, R, Rehman, T, Schaeffer, C, Ghaffari, G, Kelbel, T, Reddy, V, Buyantseva, L, Mende, C, Jose, J, Novchicht, T, Li, HH, Scarupa, M, Economides, A, White, M, Kaliner, M, Ward, C, Shaikh, S, Johnson, T, Kosh, L, Dauphin, P, Baker, J, Persons, S, Newman, A, Noonan, MJ, Lumry, WR, Poarch, KP, Tucker, J, Aguilar, D, Noth, D, Bernstein, J, Bernstein, D, Evans, S, Crawford, M, McGuckin, SD, McCollum, JR, Bradley, B, Wagner, C, Cartwright, A, Bonner, J, Soong, W, Sikora, M, Lemke, M, Luthin, P, Youngblood, B, DeBerry, E, Gilbert, E, Zhao, W, Ward, B, Alvarez, A, Kumar, S, Akl, E, Curl, J, Silva, K, Mostofi, T, Schultz, N, Manning, ME, Davis, A, Nelson, J, Levy, DS, Christiansen, SC, COMPACT Investigators
Publikováno v: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
BACKGROUND: For the prevention of attacks of hereditary angioedema (HAE), the efficacy and safety of subcutaneous human C1-esterase inhibitor (C1-INH [SC]; HAEGARDA, CSL Behring) was established in the 16-week Clinical Study for Optimal Management of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::abf1b8d2f34e89d6aa49b53d274aa3a5
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=10696
Zobrazit plný text záznamu
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke
Autor: Sacco, Rl, Diener, Hc, Yusuf, S, Cotton, D, Ounpuu, S, Lawton, Wa, Palesch, Y, Martin, Rh, Albers, Gw, Bath, P, Bornstein, N, Chan, Bp, Chen, St, Cunha, L, Dahlöf, B, DE KEYSER, J, Donnan, Ga, Estol, C, Gorelick, P, Gu, V, Hermansson, K, Hilbrich, L, Kaste, M, Lu, C, Machnig, T, Pais, P, Roberts, R, Skvortsova, V, Teal, P, Toni, Danilo, Vandermaelen, C, Voigt, T, Weber, M, Yoon, Bw, Lembo, Giuseppe, Rasura, Maurizia, Sacchetti, Maria Luisa
Publikováno v: New England Journal of Medicine, 359(12), 1238-1251. MASSACHUSETTS MEDICAL SOC
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2008, 359 (12), pp.1238-51. ⟨10.1056/NEJMoa0805002⟩
Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial; International audience; BACKGROUND: Recurrent stroke is a frequent, disabling event after ischemic stroke. This study compared the efficacy and safety of two antiplatelet reg
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71dd0e47d2f8ff41d78451c824678052
https://doi.org/10.1056/nejmoa0805002
Zobrazit plný text záznamu
5
Telmisartan to prevent recurrent stroke and cardiovascular events
Autor: Yusuf, S, Diener, Hc, Sacco, Rl, Cotton, D, Ounpuu, S, Lawton, Wa, Palesch, Y, Martin, Rh, Albers, Gw, Bath, P, Bornstein, N, Chan, Bp, Chen, St, Cunha, L, Dahlöf, B, DE KEYSER, J, Donnan, Ga, Estol, C, Gorelick, P, Gu, V, Hermansson, K, Hilbrich, L, Kaste, M, Lu, C, Machnig, T, Pais, P, Roberts, R, Skvortsova, V, Teal, P, Toni, Danilo, Vandermaelen, C, Voigt, T, Weber, M, Yoon, Bw, Lembo, Giuseppe, Rasura, Maurizia, Sacchetti, Maria Luisa
Publikováno v: New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2008, 359 (12), pp.1225-37. 〈10.1056/NEJMoa0804593〉
New England Journal of Medicine, Massachusetts Medical Society, 2008, 359 (12), pp.1225-37. ⟨10.1056/NEJMoa0804593⟩
New England Journal of Medicine, 359(12), 1225-1237. MASSACHUSETTS MEDICAL SOC
Background: Prolonged lowering of blood pressure after a stroke reduces the risk of recurrent stroke. In addition, inhibition of the renin-angiotensin system in high-risk patients reduces the rate of subsequent cardiovascular events, including stroke
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c9ada1720b25d6ae649058a332967a5
https://hal-unilim.archives-ouvertes.fr/hal-00626465
Zobrazit plný text záznamu
7
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke
Autor: Hacke, Werner, Kaste, Markku, Bluhmki, Erich, Brozman, Miroslav, Dávalos, Antoni, Guidetti, Donata, Larrue, Vincent, Lees, Kennedy R., Medeghri, Zakaria, Machnig, Thomas, Schneider, Dietmar, Von Kummer, Rüdiger, Wahlgren, Nils, Toni, Danilo, Hacke, W, Dávalos, A, Kaste, M, von Kummer, R, Larrue, V, Toni, D, Wahlgren, N, Lees, Kr, Heiss, Wd, Lesaffre, E, Orgogozo, Jm, Bastianello, S, Wardlaw, Jm, Peyrieux, Jc, Sauce, C, Medeghri, Z, Mazenc, R, Machnig, T, Bluhmki, E, Aichner, F, Alf, C, Baumhackl, U, Brainin, M, Eggers, C, Gruber, F, Ladurner, G, Niederkorn, K, Noistering, G, Willeit, J, Vanhooren, G, Blecic, S, Bruneel, B, Caekebeke, J, Laloux, P, Simons, Pj, Thijs, V, Bar, M, Dvorakova, H, Vaclavik, D, Boysen, G, Andersen, G, Iversen, Hk, Traberg-Kristensen, B, Marttila, R, Sivenius, J, Trouillas, P, Amarenco, P, Bouillat, J, Ducrocq, X, Giroud, M, Jaillard, A, Larrieu, Jm, Leys, D, Magne, C, Mahagne, Mh, Milhaud, D, Sablot, D, Saudeau, D, Busse, O, Berrouschot, J, Faiss, Jh, Glahn, J, Görtler, M, Grau, A, Grond, M, Haberl, R, Hamann, G, Hennerici, M, Koch, H, Krauseneck, P, Marx, J, Meves, S, Meyding-Lamadé, U, Ringleb, P, Schneider, D, Schwarz, A, Sobesky, J, Urban, P, Karageorgiou, K, Komnos, A, Csányi, A, Csiba, L, Valikovics, A, Agnelli, G, Billo, G, Bovi, P, Comi, G, Gigli, G, Guidetti, D, Inzitari, D, Marcello, N, Marini, C, Orlandi, G, Pratesi, M, Rasura, M, Semplicini, A, Serrati, C, Tassinari, T, Brouwers, Pj, Stam, J, Naess, H, Indredavik, B, Kloster, R, Czlonkowska, A, Kuczyńska-Zardzewialy, A, Nyka, W, Opala, G, Romanowicz, S, Cunha, L, Correia, C, Cruz, V, Pinho e Melo, T, Brozman, M, Dvorak, M, Garay, R, Krastev, G, Kurca, E, Alvarez-Sabin, J, Chamorro, A, del Mar Freijo Guerrero, M, Herrero, Ja, Gil-Peralta, A, Leira, R, Martí-Vilalta, Jl, Masjuan Vallejo, J, Millán, M, Molina, C, Mostacero, E, Segura, T, Serena, J, Vivancos Mora, J, Danielsson, E, Cederin, B, Von, Zweigberg, Wahlgren, Ng, Welin, L, Lyrer, P, Bogousslavsky, J, Hungerbühler, Hj, Weder, B, Ford, Ga, Jenkinson, D, Macleod, Mj, Macwalter, Rs, Markus, Hs, Muir, Kw, Sharma, Ak, Walters, Mr, Warburton, Ea
Publikováno v: New England journal of medicine, 359(13), 1317-1329. Massachussetts Medical Society
University of Helsinki
Background Intravenous thrombolysis with alteplase is the only approved treatment for acute ischemic stroke, but its efficacy and safety when administered more than 3 hours after the onset of symptoms have not been established. We tested the efficacy
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3ea20e0593c5dfdd726b14eedce76ea
https://pubmed.ncbi.nlm.nih.gov/19172718
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje